Breast Cancer — Triple Assessment, Mastitis Unresponsive to Antibiotics, and Determination of Subtype

THE FUNDAMENTAL PRINCIPLE THAT PREVENTS DELAYED DIAGNOSIS IN BREAST CANCER IS TRIPLE ASSESSMENT: CLINICAL EXAMINATION + IMAGING + TISSUE SAMPLING | THE MOST COMMON MISTAKE IS BREAKING THIS UNITY | TYPICAL FLOW: the patient applies due to a PALPABLE MASS → IMAGING IS REQUESTED → RESULT COMES BACK NORMAL → BOTH PATIENT AND DOCTOR RELAX and THE PROCESS ENDS THERE | HOWEVER, A NORMAL IMAGING RESULT DOES NOT MEAN THAT THE MASS DOES NOT EXIST | REASON: the sensitivity of mammography DEPENDS ON THE DENSITY OF BREAST TISSUE — IN DENSE BREAST TISSUE, THE TUMOR AND NORMAL TISSUE LOOK SIMILAR AND THE MASS MAY NOT BE NOTICED | This is MORE EVIDENT IN YOUNG WOMEN because BREAST TISSUE BECOMES FATTY WITH AGE | RULE: A PERSISTENT AND SUSPICIOUS MASS DETECTED BY PALPATION REQUIRES TISSUE SAMPLING EVEN IF IMAGING IS NORMAL | CHARACTERISTICS OF A SUSPICIOUS MASS: PERSISTENT | HARD | IRREGULARLY BORDERED | FIXED (adhered to tissue) | The choice of imaging depends on AGE and BREAST DENSITY and MUST BE VERIFIED BY INSTITUTIONAL PROTOCOL

Using triple assessment as a whole is the fundamental principle that prevents delayed diagnosis in breast cancer, and the most common mistake is breaking this integrity. The patient presents due to a palpable mass, imaging is requested, and if the result comes back normal, both the patient and doctor relax and the process ends. However, a normal imaging result does not mean the mass does not exist; the sensitivity of mammography depends on breast density, and in dense tissue, the tumor and normal tissue appear similar. This situation is more evident in young women because breast tissue fattens with age. A persistent and suspicious mass detected by palpation requires tissue sampling even if imaging is normal.

THE FASTEST HARMFUL DIAGNOSTIC DELAY IN BREAST CANCER; because THIS FORM PROGRESSES MUCH FASTER THAN OTHERS | THE CLINICAL PICTURE RESEMBLES AN INFECTION: the breast may REDDEN, HEAT UP, SWELL, and BE PAINFUL | ORANGE PEEL APPEARANCE is typical | IN THE FACE OF THIS APPEARANCE, STARTING AN ANTIBIOTIC IS A REASONABLE FIRST STEP and MOST OF THE TIME CORRECT IN A BREASTFEEDING WOMAN | THE PROBLEM ARISES WHEN THERE IS NO RESPONSE: A SECOND ANTIBIOTIC IS TRIED, THEN A THIRD, and WEEKS PASS | HOWEVER, THIS PICTURE IS ALREADY SUSPICIOUS IN A WOMAN OUTSIDE THE LACTATION PERIOD; EVEN IN A BREASTFEEDING WOMAN, FAILURE TO RESPOND TO TREATMENT CHANGES THE SITUATION | RULE — THE LIMIT IS KEPT OPEN: A 'MASTITIS' THAT DOES NOT RESPOND TO ANTIBIOTICS or IS NOT DURING LACTATION IS CANCER UNTIL PROVED OTHERWISE AND REQUIRES TISSUE SAMPLING | THIS DECISION SHOULD NOT BE DELAYED

Mistaking inflammatory breast cancer for mastitis is the most rapidly harmful diagnostic delay because this form progresses much faster. The picture resembles an infection; the breast reddens, heats up, and swells, and orange peel appearance is typical. Starting an antibiotic is a reasonable first step, and in a breastfeeding woman, it is correct most of the time; the problem arises when there is no response, as weeks pass while a second and third antibiotic are tried. Yet, this picture is already suspicious in a woman outside the lactation period, and even in a breastfeeding woman, the lack of response changes the situation. A mastitis picture that does not respond requires tissue sampling, and this decision should not be delayed.

The determination of treatment by the SUBTYPE makes it impossible to consider breast cancer as a single disease, and THIS INFORMATION IS READILY AVAILABLE IN THE BIOPSY REPORT | If two tumors of the SAME SIZE and SAME STAGE have different subtypes, they receive ENTIRELY DIFFERENT TREATMENTS and follow ENTIRELY DIFFERENT COURSES | HORMONE RECEPTOR POSITIVE forms generally progress MORE SLOWLY and benefit from HORMONE THERAPY; this treatment lasts for YEARS | HER2 POSITIVE forms, which were previously considered POORLY PROGNOSTIC, have significantly CHANGED WITH TARGETED THERAPIES | TRIPLE NEGATIVE forms are more AGGRESSIVE and DO NOT BENEFIT FROM THESE TWO TREATMENT OPTIONS | RULE: the physician monitoring the patient MUST READ THE REPORT and KNOW THE SUBTYPE — ONLY WITH THIS INFORMATION can it be understood WHY the patient RECEIVED WHICH TREATMENT | MALE BREAST CANCER — the reason for delay is more DUE TO LACK OF EXPECTATION THAN LACK OF INFORMATION: breast cancer EXISTS IN SOCIETY and IN THE MINDS OF PHYSICIANS AS A FEMALE DISEASE → when a male patient presents with swelling in the breast area, the FIRST THOUGHT IS GYNECOMASTIA, which IS OFTEN CORRECT | EXAMINATION FINDINGS THAT DIFFERENTIATE: GYNECOMASTIA — directly under the NIPPLE, SOFT CONSISTENCY, OFTEN BILATERAL | CANCER — UNILATERAL, HARD, IRREGULARLY BORDERED, AWAY FROM THE NIPPLE , ATTACHED TO TISSUE | A mass with these characteristics IS NOT CONSIDERED GYNECOMASTIA; MALE CASES also REQUIRE GENETIC COUNSELING

The subtype determining the treatment makes it impossible to consider breast cancer as a single disease. If two tumors of the same size and stage have different subtypes, they receive entirely different treatments and follow different courses; hormone receptor-positive forms progress more slowly and benefit from hormone therapy lasting years, the course of HER2 positive forms has significantly changed with targeted therapies, whereas triple-negative forms are more aggressive. The physician must read the report and know the subtype. In male breast cancer, the reason for delay is lack of expectation; gynecomastia is under the nipple and soft, whereas cancer is unilateral, hard, and away from the nipple.

CORRECT INTERPRETATION OF NIPPLE CHANGES DETECTS BREAST CANCERS WITHOUT MASSES | DISCHARGE IS A COMMON COMPLAINT and THE MAJORITY ARE BENIGN; THEIR CHARACTERISTICS HELP IN DISTINGUISHING | BENIGN TENDENCY: BILATERAL | FROM MULTIPLE DUCTS | MILKY | BUT OCCURS WHEN COMPRESSED → usually due to a HORMONAL cause | SUSPICIOUS: UNILATERAL | FROM A SINGLE DUCT | SPONTANEOUSLY DISCHARGING | BLOODY → SHOULD BE INVESTIGATED | SEPARATE SIGNIFICANT FINDING — STUBBORN CHANGE RESEMBLING ECZEMA ON AND AROUND THE NIPPLE: this appearance is TRYING TO BE TREATED as a SKIN DISEASE WITH CORTICOSTEROID CREAMS, WHILE THERE MAY BE UNDERLYING CANCER → IN CASES WITH NO RESPONSE, TISSUE SAMPLING IS NECESSARY | PREGNANCY AND BREASTFEEDING — DELAY CAUSED BY BOTH PATIENT AND DOCTOR: during pregnancy, breast tissue ENLARGES, HARDENS, and FEELS IRREGULAR; during breastfeeding, BLOCKAGES IN MILK DUCTS and MASS-LIKE HARDNESSES are common → a mass detected in this situation IS CONSIDERED A NATURAL CHANGE and MONITORED; the patient thinks similarly and DELAYS CONSULTATION | HOWEVER, CANCER CAN ALSO BE SEEN DURING THESE PERIODS → A PERSISTENT MASS should be investigated WITHOUT DELAY during these periods; IMAGING and TISSUE SAMPLING CAN BE DONE in pregnancy with appropriate methods | LATE EFFECTS OF TREATMENT — these patients LIVE FOR MANY YEARS AFTER TREATMENT AND THE PROBLEMS THEY ENCOUNTER ARE MORE THE TRACES OF THE TREATMENT THAN THE DISEASE ITSELF: AXILLARY SURGERY and RADIATION THERAPY DISTURB LYMPH FLOW → PERMANENT SWELLING can develop in that arm and A SMALL CUT CAN TURN INTO A SERIOUS SOFT TISSUE INFECTION | HORMONE THERAPIES ARE USED FOR YEARS and affect BONE DENSITY, VASCULAR HEALTH, and QUALITY OF LIFE | IN YOUNG PATIENTS, EARLY MENOPAUSE and LOSS OF FERTILITY may arise → THIS TOPIC IS DISCUSSED BEFORE STARTING TREATMENT | PSYCHOLOGICAL EFFECTS are common and ARE NOT EXPRESSED UNLESS ASKED DIRECTLY

Correct interpretation of nipple changes detects cancers without masses. Bilateral, multi-duct, milky, and expressible discharge is usually hormonal; unilateral, single-duct, spontaneous, and bloody discharge is suspicious. Eczema-like persistent changes on the nipple are often tried to be treated with corticosteroid creams, whereas there may be underlying cancer. During pregnancy and breastfeeding, since the breast has already changed, detected lumps are considered normal and the patient may postpone seeking care, whereas cancer can also occur during these periods and evaluation should not be delayed. Treatment late effects include lymphedema, effects of hormone therapy on bones and vessels, early menopause, and psychological effects.